From the Desk of Ian Culley @IanCulley

It’s a new year with unlimited possibilities!

Even ol’ King Dollar is turning the page, embracing 2024 and everything it offers with open arms. It’s shaken off the selling pressure from 2023 and appears ready to turn over a new leaf. 

But a bigger dollar rally might need a little help from a nearby friend. 

More on this idea in a second. 

First, let’s check out the US Dollar Index $DXY chart…

The DXY is finding its footing following a brutal holiday season (dropping nearly 5 percent since November 17):

The DXY stopped catching lower right where we would expect: a shelf of former lows at approximately 101.

A period of US dollar strength would make sense as the DXY mean reverts higher, especially as it enters its most favorable month of the year.

Dollar strength likely means...

From the Desk of Steve Strazza and Alfonso Depablos

The only transaction on today’s list comes in a 13G filed  by Riposte Capital.

The firm increased its stake in SilverBow Resources $SBOW from 7.75% to 9.70%.

Healthcare is an early leader out of the clubhouse to start the year. We've already seen some big moves in names like Merck, Amgen, and Lilly.

This is a sector rotation that makes sense to us. And for this reason, today's trade is in a name we think will play catchup to these leaders.

But first, lets zoom out to observe this chart of $PFE, highlighting the stock sitting near a level that has acted as strong support for numerous times over the past decade:

In today's Daily Digest, we'll review:

1. New Position in USO.
2. No adjustments today.
3. No exits since the last report.
4. Current status of open campaigns.

Let's dig in!

It's a new year. But does that mean we need to see new trends?

Well I think we're definitely going to see new trends emerging. But I have a strong suspicion that a lot of the old trends will remain in place as well.

If you recall, back in July we were looking at a bunch of the leading groups running into their former highs from late 2021.

These groups included Industrials, Semiconductors, Homebuilders and Mega-cap Technology.

From the Desk of Steve Strazza and Alfonso Depablos

The largest transaction on today’s list comes in a Form 4 filing by James F. Lynch, director  of Globalstar Inc $GSAT.

Lynch reported a purchase of GSAT shares with a total value of $963,700.

From the Desk of Steve Strazza @Sstrazza

Welcome to The Minor Leaguers.

We've had some great trades come out of this small-cap-focused column since we launched it back in 2020 and started rotating it with our flagship bottom-up scan, Under the Hood.

For the first year or so, we focused only on Russell 2000 stocks with a market cap between $1 and $2B.

That was fun, but we wanted to branch out a bit and allow some new stocks to find their way onto our list.

We expanded our universe to include some mid-caps.

To make the cut for our Minor Leaguers list now, a company must have a market cap between $1 and $4B.

And it doesn't have to be a Russell component — it can be any US-listed equity. With participation expanding around the globe, we want all those ADRs in our universe.

The same price and liquidity filters are applied. Then, as always, we sort by proximity to new highs in order to...

This is the video recording of our January 2nd Monthly Charts Live Strategy Session

From the Desk of Steve Strazza @sstrazza and Alfonso Depablos @Alfcharts

This is one of our favorite bottom-up scans: Follow the Flow.

In this note, we simply create a universe of stocks that experienced the most unusual options activity — either bullish or bearish, but not both.

We utilize options experts, both internally and through our partnership with The TradeXchange. Then, we dig through the level 2 details and do all the work upfront for our clients.

Our goal is to isolate only those options market splashes that represent levered and high-conviction, directional bets.

We also weed out hedging activity and ensure there are no offsetting trades that either neutralize or cap the risk on these unusual options trades.

What remains is a list of stocks that large financial institutions are putting big money behind.

And they’re doing so for one reason only: because they think...

From the Desk of Ian Culley @IanCulley

The first day of trading is full of uncertainty and excitement. 

Aren’t they all!

Yet the new year brings one promise: events that have yet to come.

As corny as it sounds, it’s true.

Sure, precious metal bulls see new all-time highs for gold on the horizon.

I’m right there with them.

But let’s not get ahead of ourselves on day one.

Instead, let’s start the year with a long-term chart of gold…

From the Desk of Steve Strazza and Alfonso Depablos

The largest transaction on today’s list comes in a Form 4 filing by James F. Lynch, director  of Globalstar Inc $GSAT.

Lynch reported a purchase of GSAT shares with a total value of $963,700.

In today's Daily Digest, we'll review:

1. No new positions today.
2. Defensive adjustment in XLV.
3. No exits since the last report.
4. Current status of open campaigns.

Let's dig in!

From the Desk of Ian Culley @IanCulley

The first day of trading is full of uncertainty and excitement. 

Aren’t they all!

Yet the new year brings one promise: events that have yet to come.

As corny as it sounds, it’s true.

Sure, precious metal bulls see new all-time highs for gold on the horizon.

I’m right there with them.

But let’s not get ahead of ourselves on day one.

Instead, let’s start the year with a long-term chart of gold…

Here’s a monthly candlestick chart zoomed out roughly 30 years:

The main takeaway to start the year: Gold has yet to break out. 

Yes, gold recently hit a new all-time high. But it will remain a range-bound mess until buyers absorb supply at approximately 2,100. 

We can talk about gold 2,500 or 3,250 once it clears that critical supply zone.

Meanwhile, silver mining stocks are showing strength. 

The Silver Miners ETF $SIL is struggling to hold last week’s breakout as the US dollar bounces off a former support level.

We can expect near-term weakness for precious metals when the USD catches a bid, especially the...

From the Desk of Steve Strazza and Alfonso Depablos

The most significant transaction on today’s list comes in a Form 4 filing by Venrock Healthcare Capital Partners.

The firm reported a purchase of roughly $6.4 million in KalVista Pharmaceuticals Inc $KALV.

2023 turned out to be a great year for investors.

It was really hard not to make a lot of money last year.

And while the trends for stocks and many other risk assets are certainly up, we want to be identifying what the market will have to do for us to position ourselves much more defensively into the new year.

The first warning of a non-so-great market environment would be a breakdown in the Nasdaq100 and Small-cap Russell2000.

Look at those former highs in QQQ from late 2021. If the Nasdaq100 ETF is below 400, that would put it back below those former highs, increasing the vulnerability for further downside, or even a grind sideways.

From the Desk of Steve Strazza and Alfonso Depablos

The most significant transaction on today’s list comes in a Form 4 filing by Venrock Healthcare Capital Partners.

The firm reported a purchase of roughly $6.4 million in KalVista Pharmaceuticals Inc $KALV.